ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 113 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $275,000 | -8.3% | 18,965 | +26.1% | 0.06% | 0.0% |
| Q2 2018 | $300,000 | +23.0% | 15,044 | +51.8% | 0.06% | +43.9% |
| Q4 2017 | $244,000 | -45.7% | 9,908 | -44.3% | 0.04% | -36.9% |
| Q3 2017 | $449,000 | -11.3% | 17,791 | -4.7% | 0.06% | -4.4% |
| Q2 2017 | $506,000 | +25.2% | 18,662 | +37.8% | 0.07% | +25.9% |
| Q1 2017 | $404,000 | +82.0% | 13,546 | +65.5% | 0.05% | +80.0% |
| Q4 2016 | $222,000 | – | 8,183 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
| Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
| GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
| Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
| VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
| Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
| Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
| BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |